Bob Soh MD, GDipSurg, GAICD
Chief Operating Officer
David Kaye, MD, PhD, FACC
Chief Medical Officer
Melissa Byrne, PhD
Research & Development Manager
Bob is the Chief Operating Officer of Cardiora, bringing over 10 years of medical, clinical trial and management expertise. Concurrent to his role with Cardiora, Bob is also a member of investment team in Brandon Capital Partners, Australia’s largest life sciences VC.
Bob completed his medical training in the University of Melbourne, and subsequently undertook his surgical residency and training in major teaching hospitals across Melbourne and Sydney.
Prior to joining Cardiora, Bob was the Senior Medical Officer in Nucleus Network, Australia’s largest clinical trials unit, working closely with various international biotech and pharmaceutical companies. His roles included management, business development and clinical operations.
During his tenure in Nucleus Network, he was an investigator in over 150 trials, ranging from first in human studies through to phase 2b studies.
Bob is a Graduate of the Australian Institute of Company Directors and is a member of AusBiotech. He currently lectures in the University of Melbourne’s Department of Science and Medicine, having held teaching various teaching appointments since 2011.
David is the founder, director and Chief Medical Officer of Cardiora. Concurrent to his role in Cardiora, he is a heart failure cardiologist, and is the Director of Cardiology in the Alfred Hospital, Head of the Cardiology Division and an NHMRC Senior Principal Research Fellow at the Baker Heart Research Institute. He is a Fellow of the Royal Australasian College of Physicians and Fellow of the European Society of Cardiology.
David is recognised internationally for his work on the pathophysiology of heart failure. His studies have identified a range of the fundamental mechanisms that contribute to the progressive nature of heart failure. He has published over 340 research articles, with over 23,000 citations.
David has a proven history in translational research. He is the inventor of two other medical devices, which led to the formation of Cardiac Dimensions and Osprey Medical. David was awarded the Eric Sussman and RT Hall Prizes in 2003 for research excellence from the College of Physicians and Cardiac Society, and also the Eureka Prize for Medical Research Translation in 2012.
Melissa joined Cardiora in 2016, bringing 15 years of research and development, operational and management expertise. Concurrent to her role in Cardiora, Melissa heads up the large animal research program for the Baker Heart Research Institute, and is also an investment analyst in Brandon Capital Partners.
Melissa has a first class honours degree in science, and a Ph.D in cardiovascular physiology from Monash University. She subsequently completed her research fellowship at Johns Hopkins Medicine, Baltimore, where her work focused on the translation of basic sciences into pre-clinical research and longer term clinical outcomes. Her work was pivotal for the commercialization and development of a number of cardiology treatments currently on market or in clinical development.
Melissa has a Graduate Certificate in Research Commercialisation is an honorary Fellow in the Faculty of Veterinary Science, University of Melbourne and an Adjunct Fellow in the Faculty of Medicine, Monash University.
Alan Parr, PhD
CMC and Formulation Specialist
Chris Nave, PhD
Ingmar Wahlqvist, MD, MBA, GAICD
Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund.
Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.
Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned
subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry.
In October 2014, Chris was awarded the AusBiotech Johnson & Johnson Industry Leadership Award, announced during the Ausbiotech Conference on the Gold Coast. In addition to Cardiora, Chris is currently a Director of Certa Therapeutics, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, Athena Medicines, QueOncology Pty Ltd, Azura Ophthalmics and EBR Systems Inc. Chris was also Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis.
Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.
Ingmar is an investment manager with Brandon Capital Partners since 2009. Immediately prior to this, he worked as a Business Development Manager at Melbourne Ventures, commercialising technology from the University of Melbourne, a position which included a part-time secondment to GBS Venture Partners, a life-science venture capital group.
Before that, Ingmar spent several years working in the global commercial operations of Sanofi-Aventis in Paris, France, the majority in the cardiovascular franchise of global marketing, and in particular on Plavix, which during this time grew to be the second best-selling drug worldwide. Ingmar also worked with a number of early-stage companies in the health sector, and as a management consultant with The Boston Consulting Group, advising clients in a range of industries including financial services, airlines and manufacturing. He spent some years working in clinical medicine, largely in critical care (emergency, intensive care, anaesthetics) within major teaching hospitals.
Ingmar is a Director of Protego Medical Pty Ltd, an Alternative Director for PolyActiva P/L, and is a past Director of Med-e-Serv P/L. Ingmar earned his medical degree (MB BS) from Monash University, and his Masters of Business Administration (MBA) from Melbourne Business School, where he graduated with an Award of Distinction. He is a registered medical practitioner with the Medical Board of Australia, a Graduate of the Australian Institute of Company Directors and a member of AusBiotech.
Alan joined the Cardiora team in 2017, bringing over 30 years of experience in formulation design and CMC.
Alan completed is Pharm.D. degree from the University of Nebraska College of Pharmacy and his Ph.D. from the University of Kentucky College of Pharmacy. Alan built his career with GlaxoSmithKline (previously Glaxo, GlaxoWellcome), starting as a formulation scientist, eventually assuming the role of formulation manager, and eventually Director of Biopharmaceutics, where his responsibilities ranged from development of formulations from the early development phase all the way through to the scale up of commercial size batches for the marketplace.
Alan was intimately involved with the creation, review and submission of regulatory documents to the US Food and Drug Administration, including Investigational New Drug (IND) applications, New Drug Applications (NDA) as well as foreign filings (Marketing Authorization Applications (MAA)).
Guy Krippner, PhD
Guy is currently Head of the Medicinal Chemistry Facility at Baker IDI. He has 15 years of experience as a senior Medicinal Chemist within the Biotechnology industry; 7 years of which have been as Head of Medicinal Chemistry within three different organisations.
He has participated in and managed a diverse range of drug discovery and development projects at Biota Holdings, Prana Biotechnology Ltd Starpharma Ltd and Verva Pharmaceuticals Ltd and is currently responsible for the provision of medicinal chemistry services as a core facility to the research programs of Baker IDI. Dr Krippner is an inventor on 11 patent families.
William T Abraham MD Ohio State University
Sanjiv J. Shah MD North Western University
Dalane Kitzman MD Wake Forest Baptist Health
Daniel Burkhoff MD Cardiovascular Research Foundation